Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000933 · ClinicalTrials.gov registry record
Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048
A clinical trial of HIV Infections and Pneumococcal Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 326
- Enrollment target
- 15
- Study locations
NCT00000933 is a study of HIV Infections and Pneumococcal Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 326 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (27% lower). The trial reports 15 study locations across 13 states.
The verdict
NCT00000933, a study of HIV Infections and Pneumococcal Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 326 participants
- Enrollment target
- 15
- Study locations
Study Summary
Some people who have taken azithromycin to prevent MAC (Mycobacterium avium Complex, a bacterial infection common in HIV-infected persons) have been found to carry antibiotic-resistant bacteria (germs that grow despite the presence of drugs used to kill them). The purpose of this study is to see if people who take azithromycin carry more antibiotic-resistant bacteria than people who have chosen to delay MAC preventive therapy. When bacteria like Streptococcus (a type of bacteria that causes pneumonia and meningitis) are frequently exposed to antibiotics, the bacteria can become resistant to the drugs. MAC preventive therapy uses antibiotics, but this can make it difficult to treat other infections caused by bacteria that have become resistant in HIV-infected persons. If MAC preventive therapy is delayed, Streptococcus in the body may be less likely to develop resistance. Therefore, if the patient does get a Streptococcus infection, it will be easier to treat because it is not resistant to the antibiotics.
Conditions Studied
Study Locations (15)
Michigan
- Wayne State Univ - WSU/DMC / Univ Hlth Ctr - Detroit
- Henry Ford Hosp - Detroit
New Jersey
- Southern New Jersey AIDS Cln Trials / Dept of Med - Camden
- North Jersey Community Research Initiative - Newark
California
- Community Consortium / UCSF - San Francisco
Colorado
- Denver CPCRA / Denver Public Hlth - Denver
District of Columbia
- Washington Reg AIDS Prog / Dept of Infect Dis - Washington D.C.
Georgia
- AIDS Research Consortium of Atlanta - Atlanta
Illinois
- AIDS Research Alliance - Chicago - Chicago
Louisiana
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Est. Completion | 2000-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000933
The ClinicalTrials.gov registry entry for NCT00000933 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (27% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.
NCT00000933 reports 15 study locations spanning 13 distinct geographic areas - top geographies include Michigan, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT00000933 about?
NCT00000933 is a clinical study titled "Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048". Some people who have taken azithromycin to prevent MAC (Mycobacterium avium Complex, a bacterial infection common in HIV-infected persons) have been found to carry antibiotic-resistant bacteria (germs that grow despite the presence of drugs used to kill them). The purpose of this study is to see if ...
What is the current status of trial NCT00000933?
This trial is currently completed. The enrollment target is 326 participants. Estimated completion is 2000-07.
What conditions does trial NCT00000933 study?
This clinical trial studies the following conditions: HIV Infections, Pneumococcal Infections, Mycobacterium Avium-Intracellulare Infection.
Who is sponsoring clinical trial NCT00000933?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000933 being conducted?
This trial has 15 study locations across California, Colorado, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.